NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O= C ([C@ H](CO) NC
(= O)[C@ H](CC (C) C) NC (= O)[C@ H](CC (O)= O) NC (= O)[C@ H](CC (C) C) NC …

The above-discussed and other draWbacks and de? cien cies of the prior art are overcome
or alleviated by an improved tissue/implant interface, comprising an implant having an outer …

BACKGROUND Many illnesses or conditions require administration of a constant or
Sustained level of a medicament or biologically active agent to provide the most effective …

Nov. 1, 2001, and a continuation-in-part of application No. and Crew LLP 09/783,253, filed
on Feb. 13, 2001, and a continuation-in part of application No. 09/782,927, filed on Feb. 13 …

3,743,604 7/1973 Schnoring ct a1~ 427/21335 as under physiological conditions. Methods
of production 3'764'477 10/1973 K1?“et a1 '""" 435/180 and methods of use for research …

US9035027B2 - Dual variable domain immunoglobulins and uses thereof - Google Patents
US9035027B2 - Dual variable domain immunoglobulins and uses thereof - Google Patents …

Microparticles formed by mixing a macromolecule with a polymer at a pH near the isoelectric
point of the macromolecule and incubating the mixture in the presence of an energy source …

4. 85 3. 224 A 8, 1989 Man O for an extended period of time. The prostamide component 4s
63.457 A 9, 1989 g may be associated with a biodegradable polymer matrix. Such 4s65s46 …

Purpose. A previous study from our group has shown that in theacidic microclimate of poly
(lactide-co-glycolide)(PLGA) implants, encapsulated BSA forms insoluble noncovalent …

An injectable depot gel composition containing a polymer, a Solvent that can dissolve the
polymer and thereby form a Viscous gel, a beneficial agent; and an emulsifying agent in the …